Introduction {#S1}
============

A property intrinsic to living organisms is a biologic circadian clock which is organized and oscillates at multiple hierarchies at both cellular ^[@R1],[@R2]^ and multi-cellular levels ^[@R3],[@R4]^ in both the animal and plant kingdoms ^[@R5],[@R6]^. In mammalian biology, many aspects of behavior and physiology follow cyclic rhythms which are generally presumed to confer adaptive advantage by coordinating behavior and organ physiology to ambient day-and-night cycles ^[@R4]^. In the kidney, significant circadian rhythms exist for multiple renal hemodynamic, glomerular and tubular parameters ^[@R7],[@R8]^. These renal circadian rhythms are influenced by external cues such as feeding, ambient light, and activity, as well as inherently by intrinsic clocks ^[@R9],[@R10]^.

In 1845, Henry Bence Jones, who is considered the pioneer of urinary chemistry for his studies of urinary light chains, glucose, and cystine in disease states ^[@R11]^, noted diurnal variation in urine pH in normal individuals ^[@R12]^. Subsequent studies also demonstrated morning alkaline and evening acidic trends of urine although this finding was not always uniformly observed ^[@R13]-[@R18]^. However, the precise circadian profile of urine acidification remains incompletely defined, and the factors responsible for hour-to-hour fluctuations in pH are not known. Gastric acid secretion with the concomitant alkalization of plasma has been proposed to be the origin of postprandial changes in plasma and urine pH 19,20. In addition, it is unclear whether renal disorders affect circadian patterns of urinary chemistry and whether such derangements in rhythmic changes in urinary acidification contribute to pathophysiology.

Although the kidney is capable of elaborating urine at an enormously wide range of hydrogen ion concentrations when stressed (pH from \<5 to \>8; \[H^+^\] from \< 10nM to \> 10 μM), normal day-to-day urine pH is poised within a much narrower span in humans somewhere between pH 5.5 and 6.5. Acidification of urine is of critical importance for prevention of calcium phosphate crystallization in the urinary space ^[@R21]-[@R23]^. However, urinary pH cannot be lowered too much because of another constraint in higher primates who maintain relatively high plasma and urinary uric acid ^[@R22],[@R24]^. Urinary acidification to below pH 5.5, while protective against calcium phosphate precipitation, poses a substantial risk of uric acid precipitation ^[@R22]^. Precipitation of calcium phosphate and uric acid thus set the upper and lower limits of urinary pH respectively and calcium phosphate and uric acid nephrolithiasis in fact represent quintessential clinical disorders of urinary pH.

In humans with uric acid nephrolithiasis, excessively acidic urine causes titration of urate to the highly insoluble uric acid despite normal or even low total uric acid content in urine. The pathogenesis of low urine pH has been ascribed to both increased acid load to the kidney and defective utilization of ammonia in urinary buffering ^[@R25]-[@R31]^. It is not clear whether the unduly acidic urine in uric acid stone formers occurs at specific intervals or persists throughout the day. Current standard clinical practice, clinical investigations, and clinical trials, all use 24-hr urine collections to assess risk for uric acid stones and adequacy of response to therapy. We reported that during treatment of uric acid nephrolithiasis with alkali, excessive nocturnal and early morning urinary acidity can linger despite apparent alkalinization of pooled 24-hr urine ^[@R32]^. This can potentially result in a false sense of security for the clinician that uric acid stone risk is eliminated but elevated propensity for uric acid precipitation still persist in the patient during specific periods of the day. While most patients likely respond to day time alkali therapy, the possibility remains in some individuals where persistent early morning aciduria can sustain the elevated stone risk despite alkali therapy.

The study of 24-hr urine profiles in uric acid stone formers will enhance our understanding of its pathophysiology and the origin of the excessive aciduria. It will also guide us in designing better clinical tests for diagnosis and monitoring of therapy in uric acid nephrolithiasis. We embarked to detail the circadian pattern of urinary acidification parameters in normal volunteers to delineate normal circadian physiology and uric acid stone formers to identity pathophysiologic defects. In addition, we tested the longstanding belief that gastric acid secretion contributes to changes in urinary pH by blocking gastric acid production in the two groups of subjects.

Results {#S2}
=======

Demographic Characteristics {#S3}
---------------------------

The demographic characteristics of the study population are depicted in [Table 1](#T1){ref-type="table"}. Ten UASF and nine HV participated in the study. Most of the subjects in both groups were male and non-Hispanic Caucasians which is typical of UASF's. The mean age did not differ significantly between the two groups. The UASF's weighed more and had a higher BMI than the HV's.

Serum and Urine Chemistry {#S4}
-------------------------

[Table 2](#T2){ref-type="table"} shows the fasting serum chemistry for both groups in each study phase. In both phases, UASF had a slightly higher serum creatinine due to higher creatinine production rate but creatinine production rate per body mass was not different between the two groups. Most importantly, creatinine clearance was not different between the two groups. Serum uric acid was persistently higher in UASF's in both phases of the study. Serum bicarbonate, chloride, and venous pH did not differ between the two groups. UASF's taking placebo demonstrated a very slight but statistically significantly higher serum potassium than in the PPI phase and higher than HV's in both phases.

Urine was collected for 24 hours prior to each diurnal study and results are shown in [Table 3](#T3){ref-type="table"}. In both study phases, urine pH in UASF was significantly lower than in HV (UASF vs. HV in placebo phase: 5.42 ± 0.36 vs. 5.86 ± 0.28; p = 0.01; UASF vs. HV in PPI phase: 5.32 ± 0.36 vs. 5.93 ± 0.23; p \< 0.001). Urinary sodium, potassium, sulfate, and phosphate did not differ among the groups indicting equivalence of dietary intake. In both phases, citrate excretion was numerically lower in UASF but the difference was not statistically significant. Twenty-four hour Titrable acidity and NAE was higher, and urinary ammonium was lower numerically in UASF compared with HV although none of the differences reached a p value of \<0.05 in this small cohort. However, the proportion of NAE as ammonium (NH~4~/NAE) was significantly lower in UASF (UASF vs. HV in placebo phase: 0.55 ± 0.08 vs. 0.75 ± 0.07; p = 0.003; UASF vs. HV in PPI phase: 0.55 ± 0.15 vs. 0.78 ± 0.16, p = 0.001). Twenty-four hour urinary uric acid excretion did not differ between the groups. There was no difference between the placebo and PPI phase.

Diurnal Study {#S5}
-------------

[Figures 1A and B](#F1){ref-type="fig"} depict the diurnal urine pH in the HV and UASF group under each study phase. Throughout the day, both HV and UASF demonstrated marked variations in urine pH. In both groups, urine pH increased in the morning, peaked at noon, fell following lunch, rose again during the afternoon, and fell again after the evening meal. A nocturnal peak in urine pH was usually seen around 22:00. Throughout the night, UpH decreased to a nadir around 06:00 before rising again in the morning. Changes in urine pH over time are statistically significant within HV and UASF group in either the placebo or PPI phases (HV-placebo HV-PPI, UASF-placebo, UASF-PPI all p\<0.001). The shape of the curves did not differ between the placebo and PPI phases for both HV and UASF (p=0.95). PPI treatment has no effect on the value or profile of urine pH at all (p=0.60 for HV; p=0.72 for UASF)

Throughout the day, urine pH was significantly lower in UASF than in HV in either the placebo ([Figure 1C](#F1){ref-type="fig"}) or PPI phase (similar to placebo; not shown) (p\<0.001). However, the time profile of urine pH was not statistically different between the two groups (HV vs. UASF; p=0.14) in placebo phase. In contrast to HV on PPI, the UASF receiving PPI demonstrated a slightly blunted curve in the evening and overnight (p=0.05).

[Figure 2](#F2){ref-type="fig"} compares urinary excretion rates of principal acid-base components in HV and UASF during the placebo phase. Since there was no difference between PPI and placebo, only the placebo phase is shown. In both HV and UASF, excretion of these solutes varied significantly over time (all p\<0.001). Acid excretion in general is higher in the late afternoon and evening likely reflecting the fact that the protein for breakfast is less than that of lunch and dinner (gms of protein: breakfast 7, lunch 24, dinner 30). Urinary ammonium excretion rate ([Figure 2A](#F2){ref-type="fig"}) did not differ between HV and UASF in regards to both amount (p=0.11) and pattern (p=0.40). The pattern of TA excretion also did not differ between the groups (p=0.27). However, the amount of TA was significantly higher in the UASF group (p=0.005) ([Figure 2B](#F2){ref-type="fig"}). The amount and pattern of the two urinary bases differed between the groups. USAF excreted less bicarbonate (p=0.01) and had a flatter bicarbonate profile (p=0.05) compared HV ([Figure 2C](#F2){ref-type="fig"}). In addition, UASF excreted significantly less citrate (p=0.012) and tended to have a different citrate pattern (p=0.056) with blunted citrate excretion in the UASF occurring mostly in the morning.

Plasma bicarbonate concentration changed significantly during the 24 hour period (p\<0.001 for both groups) but the pattern was similar in HV and UASF (p=0.94) ([Figure 3A](#F3){ref-type="fig"}). However, serum bicarbonate was higher in HV compared to UASF throughout the day (p=0.003). There were no differences between the PPI and placebo phase in either NV or UASF for both pH and bicarbonate so only the placebo data is shown in [Figure 3](#F3){ref-type="fig"}. Interestingly, despite the differences in bicarbonate concentrations, changes in venous pH over time did not reach statistical significance within either group during the two treatment periods (p=0.21) and did not differ between the groups (p=0.45) ([Figure 3B](#F3){ref-type="fig"}). UASF have higher NAE than HV even though they are on identical metabolic diets ([Figure 4A](#F4){ref-type="fig"}). The equivalence of dietary acid load is proven by the same amount and pattern of sulfate excretion ([Figure 4B](#F4){ref-type="fig"}). Although exogenous dietary acid load was equivalent, UASF have consistently higher acid excretion throughout the day with the exception of perhaps the period around 18:00-20:00 in the evening. This is best illustrated by the consistently higher NAE/sulfate ratio throughout the day in UASF ([Figure 4C](#F4){ref-type="fig"}) (p= 0.02). The higher acid load is also compatible with the lower citrate excretion ([Figure 2D](#F2){ref-type="fig"}). Potassium excretion can be used as a surrogate for dietary alkali intake. UASF have the same potassium excretion as HV's but lower citrate excretion per K ingested (p=0.001) ([Figure 4D](#F4){ref-type="fig"}).

[Figure 5](#F5){ref-type="fig"} shows the most important determinant of uric acid stone risk in the UASF. Absolute rates or patterns of total uric acid excretion did not differ between the two groups (p=0.45) and there was no difference in the time profile in excretion between the two groups (p=0.7) ([Figure 5A](#F5){ref-type="fig"}). However, UASF had persistently about twice the undissociated uric acid content in urine as HV ([Figure 5B](#F5){ref-type="fig"}) (p\<0.001).

Discussion {#S6}
==========

Instead of examining pooled 24 hr samples, we tried to define circadian variation of urine pH and acid-base parameters in healthy subjects as well as in uric acid stone formers. We also examined the contribution of gastric acid secretion on circadian variation in both groups and evaluated whether differences in gastric acid secretion are responsible for a lower urine pH in UASF vs. HV.

Both HV's and UASF's were placed on a strict metabolic diet thereby eliminating exogenous factors on acid-base balance. Both groups demonstrated significant variations in urine pH throughout the day, and these changes were temporally related to meals. Although there was little change immediately following breakfast, urine pH declined after the noon and evening meals. Urine pH subsequently rose and peaked approximately four hours after each meal. Overnight urine pH fell steadily, before it began to rise in the early morning hours. While they confirm the previously described "morning alkaline tide", our data did not demonstrate a true post-prandial alkaline tide in either blood or urine. A rise in serum pH after the ingestion of a meal was described previously ^[@R19],[@R20]^ while there is conflicting evidence for whether there is a consistent post-prandial alkaline tide in the urine ^[@R33],[@R34]^. This difference may, in part, be due to variances in diet, timing of urine collections ^[@R35]^, and use of pH paper to define urinary pH in some studies ^[@R33],[@R34]^. In our study, the higher frequency of urine collections allowed for a higher resolution and the instant measurement using a pH electrode permitted more accurate assessment of circadian changes. The decline in urine pH following lunch and dinner may not have been appreciated previously, because of longer post-prandial urine collection times.

The post-prandial alkaline tide described in serum raises expectations that a similar phenomenon might occur in the urine due to increased filtered bicarbonate load. However, there are multiple factors that contribute to urine pH. The increased filtered load of HCO~3~^−^ may or may not exceed tubular reabsorption and the production and excretion of non-bicarbonate buffers will also affect UpH significantly. The effects of variations in diet are also unclear. The urine pH may reflect the combined effects of gastric acid and pancreatic bicarbonate secretion, and the extent of each process may alter urine pH. Others have shown that in patients after vagotomy, receiving H2-blockers or PPI, have varying degrees of blunted post-prandial alkaline tide in the blood ^[@R19],[@R20],[@R33],[@R34],[@R36]^. If gastrointestinal acid or base secretion was responsible for diurnal urine pH changes, then administration of a proton pump inhibitor would completely block those effects. Our study did not demonstrate any effect of the PPI medication, thus raising into question the role of gastric acid secretion in affecting urine pH. Alternative mechanisms that may account for these variations include circadian clock genes which have been found to control acid-base transporters in the kidney ^[@R37],[@R38]^. Further investigation of such genes may identify mechanisms responsible for circadian variation in urine pH.

Several features are noteworthy in the UASF's. Despite the more acidic urine, the circadian pattern is well preserved in UASF's. Unlike some previous studies reporting lack of diurnal changes in urine pH in UASF, ^[@R39],[@R40]^ we found that UASF exhibited the same peaks and troughs overnight and in relation to meals, as in HV. Previous studies were performed in a smaller number of UASF, without using strict metabolic diets, and collected urines in wider (\>6-hour) intervals. However, at each time point, UASF urine pH was significantly more acidic than HV. With the exception of two time points, UASF maintained a mean urine pH of 5.6 or less throughout all time points of the day which significantly contributes to uric acid stone development ^[@R24]^. The undissociated UA excretion rate and concentration is much higher in UASF throughout the entire 24 hr period.

Differences in the diurnal excretion of ammonium, TA, citrate and bicarbonate reflect findings previously described in pooled 24 hour urine collections ^[@R30]^ but a higher time resolution is presented in this diurnal study. UASF demonstrated lower citrate, and bicarbonate excretion and higher TA, which persisted throughout the entire day. Each urinary component exhibited a circadian pattern of excretion. The citrate and bicarbonate plots were slightly blunted in the UASF indicating possibly a different pattern of excretion. Both groups excreted ammonium and TA in a similar pattern. It has been suggested that increased acid production in UASF may account for lower urine pH ^[@R26],[@R31],[@R41]^. This mechanism may also account for consumption of base and the differences observed in the diurnal excretion of alkali.

In addition to a lower urine pH, UASF demonstrated persistently lower serum bicarbonate. This is the first demonstration that a systemic acid-base disturbance is actually present in UASF's. Serum bicarbonate measured at 8:00 am were not statistically different between the groups when analyzed as a single time point, thereby explaining why this difference may not have been previously appreciated in all published studies. However, when the sequential bicarbonate values were compared, UASF maintained significantly lower serum bicarbonate than HV throughout most of the day. These results further support the notion that in addition to a renal mechanism, systemic factor(s) such as possible increase in acid generation contribute(s) to the development of acidic urine in these patients. The origin of the increased acid load is not know yet but can be due to increased endogenous acid production, increase alkali loss in the intestine, and finally increased absorption of exogenous organic acid from perhaps colonic bacterial sources.

One weakness in this study was the discrepancy between the weights of the subject in the two groups. UASF are typically obese and because of this characteristic, finding a healthy matching group is in fact difficult. The HV included in this study were generally overweight, but not obese. It is important to note that none of our subjects showed any evidence of starvation ketosis during the study. In an attempt to improve matching, we simply analyzed the 5 HV (mean ± SD: 31.4 ± 2.2) with highest BMI against 5 subjects with lowest BMI in UASF (mean ± SD: 33.0 ± 4.3, NS), the urinary pH (HV 5.86 ± 0.20 vs. UASF 5.29 ± 0.13, p\<0.05) and the fraction of net acid excreted as ammonium (HV 0.68 ± 0.12 vs. UASF 0.54 ± 0.08, p\<0.05) are both still lower in UASF's indicating that body weight and BMI *per se* cannot account for the difference. Another drawback is that the overnight sampling did not have the same time resolution as the daytime sampling. We aimed to maximize the number of study samples without causing excessive interruption of sleep.

In conclusion, these data indicate that circadian variation in urine pH exists in both HV and UASF. Although UASF demonstrate variability in urine pH, their urine remains acidic throughout the day, leaving them unprotected from the development of uric acid stones. The etiology of the unduly acidic urine is due to a combination of a higher acid load to the kidney and the underutilization of ammonia as a buffer. One might speculate that circadian variation occurs to protect us from persistently acidic or alkaline urine pH that predisposes to stone development. Although gastric acid secretion contributes to variations in serum pH, it does not appear to affect the diurnal changes in urine pH. These results provide a foundation for future studies to determine what factors contribute to variations in urine pH, whether these persist irrespective of diet, and why UASF maintain the circadian variation but at a lower urine pH.

Methods {#S7}
=======

Study Participants {#S8}
------------------

The study was conducted at the General Clinical Research Center at the University of Texas Southwestern Medical Center (Dallas, TX) with approval by the Institutional Review Board (IRB). All participants provided informed consent. Study subjects included nine healthy volunteers (HV) who had no history of kidney stones and ten stone formers with proven uric acid stones (UASF) recruited from the Mineral Metabolism Clinic at the University of Texas Southwestern Medical Center. HV's were recruited via IRB-approved advertisements. All subjects were older than 18 years of age. Excluded from both groups were subjects with creatinine clearance \<70ml/min, proteinuria, liver disease, chronic diarrhea, peptic ulcer, or chronic use of any medications that affect gastric acid secretion or renal function. UASF's were instructed to hold all medications that affect acid or base excretion for 1 week prior to initiation of the study.

Study Protocol {#S9}
--------------

This double-blind crossover study included two 14-day phases. In the first phase, subjects were randomized to receive the long-acting proton pump inhibitor (PPI), pantoprazole, 40 mg/day, or placebo. The dose was chosen based on previous studies showing adequate suppression of gastric acid production ^[@R42]-[@R44]^. The capsules were consumed each morning with breakfast for 14 days. Participants subsequently underwent a 7 day wash out period, during which study medications were not administered, and then received the alternate study medication for 14 days in the second phase. During each phase, subjects were advised to hold blood pressure medications that might affect renal sodium excretion.

On days 8-10 of each phase, subjects were directed to consume a diet low in acid ash and sodium (\~100 mEq/day). On days 11-13 of each phase, a frozen metabolic diet was provided by the dietary services at the GCRC and consisted of 30% fat, 55% carbohydrate, 15% protein, 300 mg cholesterol, 400 mg calcium, 800 mg phosphorus, 100 mEq sodium, 40 mEq potassium, and 3000 cc distilled water per day, which subjects ingested as outpatients. From day 13 to 14, urine was collected for 24 hours under mineral oil and was refrigerated. Subjects were then admitted to the inpatient unit at the GCRC after dinner on day 13 and remained as inpatients until the morning of day 15. During the inpatient stay, subjects were maintained on the metabolic diet, although the volume of water was decreased to 2.7 L. Body weight and height was obtained at the time of admission. We monitor serum and urine ketones and detected no evidence of ketosis throughout the study.

The diurnal study was conducted on days 14 to 15. On day 14, an intravenous catheter was placed in the hand for collection of free flow blood samples. The hand was warmed in a 37°C box for 30 minutes prior to each blood draw to obtain arterialized samples. Starting at 8:00 am, urine and blood were collected every two hours throughout the day, except for the two hours following meals when samples were collected hourly. To allow subjects to have reasonable sleep overnight, samples were obtained every four hours from 22:00 until 6:00 on day 15. Thus collections were obtained at: 8:00, 9:00, 10:00, 12:00, 13:00, 14:00, 16:00, 18:00, 19:00, 20:00, 22:00, 2:00, 6:00, and 8:00. Samples were obtained prior to ingestion of meals which were provided at 8:00, 12:00 and 18:00 immediately after the blood draw at those designated times.

Timed urine samples were analyzed for total volume, pH, creatinine, electrolytes, uric acid, citrate, sulfate, ammonium, titratable acidity (TA), and bicarbonate. Blood sample measurements included serum electrolytes, creatinine, uric acid, glucose, and venous pH.

Analytical Procedures {#S10}
---------------------

A systemic multichannel analysis was performed to provide measurements of serum creatinine, sodium, potassium, chloride, total carbon dioxide, glucose, and uric acid (Beckman CX9ALX; Beckman Coulter, Fullerton, CA). Venous blood gas measurements, including serum pH and PCO~2~, were made using the Radiometer ABL 5 (Radiometer America Inc, Westlake, OH).

Urine pH was measured with a pH electrode and urine creatinine was obtained via the picric acid method. Urine and fasting serum creatinine measurements were then used to calculate endogenous creatinine clearance. An ion-specific electrode was used to measure urinary potassium (Beckman Coulter) and urine sulfate was assessed by ion chromatography. Urine ammonium was measured by the glutamate dehydrogenase method while citrate was assessed enzymatically with reagents from Boehringer-Mannheim Biochemicals (Indianapolis, IN). Urinary bicarbonate was calculated from measurements of urine pH and PCO~2~, while titratable acid was assessed by the automated burette titration system (Radiometer, Copenhagen, Denmark). Uric acid was determined via the uricase method using alkalinized samples to prevent precipitation. Net acid excretion (NAE) was calculated using the sum of ammonium and TA minus the sum of citrate and bicarbonate in mEq. The urinary anion gap (UAG) was calculated as the sum of all anions (chloride, sulfate, phosphate, urate, creatinate, oxalate, citrate, bicarbonate) subtracted from the sum of all cations (sodium, potassium, calcium, magnesium, ammonium), all in milliequivalents.

Statistical Analyses {#S11}
--------------------

Data are presented as mean ± standard deviation (SD). Demographic variables were compared between UASF and HV using the two sample t-test. Twenty four urine results and serum biochemical data were compared using mixed model repeated measures analysis followed by least square means contrasts to compare the two groups or to compare the two treatment phases.

Mixed model repeated measures analysis was also used for the diurnal studies. The models consisted of group, phase, and time main effects and interactions, with subject modeled as a random effect. An autoregressive covariance structure was used to model the repeated time effect and account for the correlation within individuals. ^[@R45]^ The interaction terms from these models were used to test for differences in diurnal pattern. The difference in diurnal pattern between the UASF and HV groups was assessed using the group-by-time interaction factor. The difference in diurnal pattern between the placebo and PPI phases was assessed using the phase-by-time interaction factor. A significant interaction (p\<0.05) indicates that the groups do not have the same pattern over time. Urine bicarbonate was rank-transformed prior to analysis. Statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC).
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###### 

Patient Demographic Data

  ------------------------------------------------------------------------------------------------------
                                         Healthy\          Uric Acid Stone\
                                         Volunteers (HV)   Formers (UASF)
  -------------------------------------- ----------------- ---------------------------------------------
  Gender: M/F                            6/3               9/1

  Race: (white / black)                  7/2               9/1

  Ethnicity: (non-Hispanic / Hispanic)   9/0               9/1

  Age (years)                            52.8 ± 13.1       57.0 ± 8.2

  Weight (kg)                            85 ± 19           109 ± 19 [\*](#TFN1){ref-type="table-fn"}

  Height (cm)                            171 ± 10          172 ± 6

  Body Mass Index (kg/m^2^)              28.5 ± 4.3        36.9 ± 6.8 [\*](#TFN1){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------

p\<0.05 t-test

###### 

Fasting Serum Profile

  -------------------------------------------------------------------------------------------------------------------------------------------------
                        Placebo        PPI                                                           
  --------------------- -------------- ---------------------------------------------- -------------- ----------------------------------------------
                        HV             UASF                                           HV             UASF

  Creatinine (mg/dL)\   0.84 ± 0.13\   1.06 ± 0.02 [a](#TFN3){ref-type="table-fn"}\   0.88 ± 0.15\   1.12 ± 0.21 [c](#TFN5){ref-type="table-fn"}\
      (μM)              74 ± 11        94 ± 1.7                                       78 ± 13        99 ± 18

  Creatinine\           139 ± 35\      131 ± 39\                                      129 ± 35\      126 ± 36\
  Clearance (ml/min)\   120 ± 20       100 ± 26                                       112 ± 17       95 ± 23
    (ml/min/1.73m^2^)                                                                                

  Glucose (mg/dL)\      97 ± 10\       103 ± 25\                                      96 ± 6\        106 ± 26\
     (mM)               5.4 ± 0.6      5.6 ± 1.4                                      5.3 ± 0.3      5.0 ± 1.4

  Uric Acid (mg/dL)\    6.0 ± 1.6\     8.0 ± 1.5 [a](#TFN3){ref-type="table-fn"}\     6.3 ± 1.6\     8.1 ± 1.5 [c](#TFN5){ref-type="table-fn"}\
     (μM)               357 ± 95       476 ± 89                                       375 ± 95       482 ± 89

  Sodium (mEq/L)        139 ± 3        138 ± 3                                        138 ± 2        138 ± 2

  Potassium (mEq/L)     4.0 ± 0.3      4.5 ± 0.7 [a](#TFN3){ref-type="table-fn"}      3.9 ± 0.2      4.0 ± 0.3 [b](#TFN4){ref-type="table-fn"}

  Chloride (mEq/L)      106 ± 3        107 ± 2                                        107 ± 2        107 ± 3

  Bicarbonate (mEq/L)   27.0 ± 1.3     26.1 ± 3.3                                     26.7 ± 1.5     25.9 ± 1.1

  Venous pH             7.41 ± 0.02    7.40 ± 0.02                                    7.41 ± 0.01    7.40 ± 0.01
  -------------------------------------------------------------------------------------------------------------------------------------------------

HV: Healthy volunteers, UASF: Uric acid stone formers

p \< 0.05 UASF vs HV; on placebo

p \< 0.05 UASF placebo vs UASF on PPI

p\< 0.05 UASF vs HV; on PPI

Comparisons made with mixed-model repeated measures analysis.

###### 

Baseline 24 hour Urine Chemistry

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Placebo          PPI                                                            
  ------------------------------- ---------------- --------------------------------------------- ---------------- ---------------------------------------------
  Total Volume (L/d)              2.77 ± 0.91      2.07 ± 0.67                                   2.69 ± 1.02      2.33 ± 0.86

  pH                              5.86 ± 0.28      5.42 ± 0.36 [a](#TFN7){ref-type="table-fn"}   5.93 ± 0.23      5.32 ± 0.36 [b](#TFN8){ref-type="table-fn"}

  Creatinine (gm/d)\              1.7 ± 0.6\       1.9 ± 0.5 [a](#TFN7){ref-type="table-fn"}\    1.6 ± 0.5\       2.0 ± 0.5\
      (mmoles/d)                  15.0 ± 5.3       18.8 ± 4.4                                    14.2 ± 4.4       17.7 ± 0.5

  Potassium (mEq/d)               43 ± 13          45 ± 12                                       45 ± 14          42 ± 13

  Sulfate (mEq/d)                 41.2 ± 9.6       41.0 ± 9.0                                    39.6 ± 10        37.4 ± 12

  Phosphate (mg/dl)\              704 ± 291\       807 ± 304\                                    683 ± 307\       789 ± 220\
      (mM)                        22.7 ± 9.4       26.0 ± 9.8                                    22.0 ± 9.9       22.5 ± 7.1

  Ammonium (NH~4~) (mEq/d)        39 ± 15          32 ± 16                                       39 ± 19          33 ± 12

  Titratable Acid (mEq/d)         24 ± 9           33 ± 9 [c](#TFN9){ref-type="table-fn"}        25 ± 11          34 ± 9 [e](#TFN11){ref-type="table-fn"}

  Citrate (mEq/d)                 9.9 ± 3.7        7.3 ± 4.8 [d](#TFN10){ref-type="table-fn"}    9.1 ± 2.2        6.2 ± 3.8 [b](#TFN8){ref-type="table-fn"}

  Bicarbonate (mEq/d)\            1.1 ± 2.1\       0.3 ± 0.9\                                    1.6 ± 2.1\       0.4 ± 1.1 [b](#TFN8){ref-type="table-fn"}\
  Median \[range\]                0 \[0 -- 5.6\]   0 \[0 -- 2.72\]                               0 \[0 -- 5.9\]   0 \[0 -- 3.3\]

  Uric Acid (mg/d)                657 ± 337        540 ± 322                                     570 ± 123        472 ± 273

  Net Acid Excretion (NAE)\       53 ± 20          58 ± 22                                       53 ± 29          60 ± 12
  (mEq/d)                                                                                                         

  NAE/Sulfate (mEq/mEq)           0.75 ± 0.07      0.55 ± 0.08[a](#TFN7){ref-type="table-fn"}    0.78 ± 0.16      0.55 ± 0.15 [b](#TFN8){ref-type="table-fn"}

  NH~4~/NAE                       0.75 ± 0.07      0.55 ± 0.08[a](#TFN7){ref-type="table-fn"}    0.78 ± 0.16      0.55 ± 0.15 [b](#TFN8){ref-type="table-fn"}

  Urinary Unmeasured\             4.5 ± 12.9       10.3 ± 8.7                                    7.8 ± 9.9        6.9 ± 11.1
  Anions (mEq/d)                                                                                                  

  Fractional Excretion of Uric\   5.9 ± 2.6        4.0 ± 2.6 [a](#TFN7){ref-type="table-fn"}     5.4 ± 2.1        3.5 ± 2.0 [b](#TFN8){ref-type="table-fn"}
  Acid (%)                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

p \< 0.05 UASF vs HV; placebo

p\< 0.05 UASF vs HV; on PPI

p = 0.08 UASF vs HV; placebo

p = 0.07 UASF vs HV; placebo

p = 0.06 UASF vs HV; on PPI

Comparisons made with mixed-model repeated measures analysis.
